CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07409272
Title field or adapter rule: {'original_value': 'A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:25.161487+00:00
Published At: 2026-09-22T00:00:00+00:00
Record Updated At: 2026-09-22
Source Retrieved At: 2026-10-31T22:17:56.788771+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Pancreatic Cancer", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-09-22", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07409272"
protocolSection.identificationModule.officialTitle: "A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['Setidegrasib plus chemotherapy'], 'description': 'Intravenous infusion', 'name': 'Setidegrasib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Placebo plus chemotherapy', 'Setidegrasib plus chemotherapy'], 'description': 'Intravenous infusion', 'name': 'Oxaliplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Placebo plus chemotherapy', 'Setidegrasib plus chemotherapy'], 'description': 'Intravenous infusion', 'name': 'Leucovorin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Placebo plus chemotherapy', 'Setidegrasib plus chemotherapy'], 'description': 'Intravenous infusion', 'name': 'Irinotecan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Placebo plus chemotherapy', 'Setidegrasib plus chemotherapy'], 'description': 'Intravenous infusion', 'name': 'fluorouracil', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Placebo plus chemotherapy', 'Setidegrasib plus chemotherapy'], 'description': 'Intravenous infusion', 'name': 'liposomal irinotecan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Placebo plus chemotherapy'], 'description': 'Intravenous Infusion', 'name': 'Placebo', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.